LT Pharma
ActiveSummary
The computed 12-month bankruptcy probability of LT Pharma is 3.4% (moderate). For LT Pharma, at least two filing cycles of the annual accounts are missing. The 2023 annual accounts show equity of €1.1m and a net result of €122,899. Equity is growing by about 15% per year across the filed financial years. Its solvency ranks better than 84% of 6,535 sector peers (NACE 47, financial year 2023). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.7mtotal assets 2023
- Equity
- €1.1m
- Profit
- €122,899
Financial health
- Bankruptcy probabilitywithin 12 months
- 3.4%
2023 figures too old to score
Structure
Accounts 445 days overdue1 of 2 deeds read
Signalsraises riskFigures for financial year 2023 (filed 10-09-2024)2 financial years not filed after the legal deadline; latest accounts 31 days late; 3 of the last 3 lateNo filing in 24 months (latest 10-09-2024)Two or more financial years not filedlowers riskLiquidity: current ratio 13.10, cash €540,978neutralFiled after the deadlineShow the evidence
Bankruptcy probability
No current score
Figures too old
The available figures for FY 2023 are too old to assess current financial health.
Filing: At least two filing cycles are missing
Financial strength, FY 2023 · tick = 2022
Strong
Solvency
91+5
equity 66.4% of total assets
Liquidity
90-3
short-term debt 4.0% · cash 32.1%
Profitability
78-1
return on assets 7.3%
Bankruptcy probability, 12 months
3.4%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.2%
12-2024: 0.2%● unchanged vs 11-2024
01-2025: 0.2%● unchanged vs 12-2024lowest value
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.4%▲ +0.2 percentage points vs 07-2025
09-2025: 0.6%▲ +0.2 percentage points vs 08-2025
10-2025: 1.1%▲ +0.5 percentage points vs 09-2025
11-2025: 1.1%● unchanged vs 10-2025
12-2025: 1.5%▲ +0.4 percentage points vs 11-2025
01-2026: 2.3%▲ +0.8 percentage points vs 12-2025
02-2026: 2.3%● unchanged vs 01-2026
03-2026: 2.3%● unchanged vs 02-2026
04-2026: 2.0%▼ -0.3 percentage points vs 03-2026
05-2026: 2.0%● unchanged vs 04-2026
06-2026: 2.0%● unchanged vs 05-2026
07-2026: 2.0%● unchanged vs 06-2026
08-2026: 2.9%▲ +0.9 percentage points vs 07-2026
09-2026: 2.9%● unchanged vs 08-2026
10-2026: 3.4%▲ +0.5 percentage points vs 09-2026highest value
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Two or more financial years not filed
Since the financial year that closed on 31-12-2024, 2 financial years are missing at the National Bank. A company this far behind goes bankrupt within the year nineteen times as often as a punctual filer.
NBB · 7 filingsPosition against the passed deadline
31-12-2024 year end31-07-2025 deadline19-10-2026 today
neutral · Filed after the deadline
The financial year that closed on 31-12-2023 was due by 31-07-2024 and was filed on 31-08-2024, 31 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 7 filingsDeviation from the deadline
2025
not filed
2024
not filed
2023
31 days late
2022
32 days late
2021
31 days late
2020
30 days late
2019
153 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 5 accounts on average 55 days after the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.
Searched, nothing found (1)
- Annual accounts filedfinancial year 2023 · full…
- Amendment of the articles · Legal-form…Capital conversion · Legal-form conversion…
- Equity above €1mequity €1.1m ▲12.4%
Financials · financial year 2023, full format
2024 annual accounts not yet filed, deadline passed on 31 July 2025 Financial year closed on 31 December 2024; filing due at the latest 7 months after the close (Companies Code art. 3:10). 2 financial years without a filing since the last one filed. Source: NBB filings, as of 19 October 2026.
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€122,899▼ 3.1%
2022 · €126,852
Working capital
€811,262▲ 9.5%
2022 · €740,837
Trend over the years
2019 to 2023, 5 financial years 2018 to 2023, 6 financial years
The operating result falls in 2023; 2023 is 3% below 2022.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result€0.2m
2023
Net result€0.1m
2023
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€1.7m
2023
Equity€1.1m
2023
Debt€0.6m
2023
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€0.8m
2023
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)7.3%
2023
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency66.4%
2023
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio13.10
2023
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line201820192020202120222023
Operating result€0.03m-€0.2m▲ 602%€0.2m▲ 12.1%€0.1m▼ 56.6%€0.2m▲ 64.5%€0.2m▼ 3.0%
Net result€0.2m-€0.4m▲ 110%€0.2mabove the sector's middle half▼ 56.6%€0.07mabove the sector's middle half▼ 57.4%€0.1mabove the sector's middle half▲ 69.3%€0.1mabove the sector's middle half▼ 3.1%
Equity€0.2m-€0.6m▲ 192%€0.8mabove the sector's middle half▲ 28.5%€0.9mabove the sector's middle half▲ 9.5%€1.0mabove the sector's middle half▲ 14.6%€1.1mabove the sector's middle half▲ 12.4%
Total assets€1.1m-€1.5m▲ 34.8%€1.6mabove the sector's middle half▲ 9.0%€1.6mabove the sector's middle half▼ 2.6%€1.6mwithin the sector's middle half▲ 3.2%€1.7mwithin the sector's middle half▲ 3.9%
Debt€0.9m-€0.9m▼ 2.6%€0.8m▼ 5.0%€0.7m▼ 14.3%€0.6m▼ 10.8%€0.6m▼ 9.6%
Working capital€0.2m-€0.5m▲ 153%€0.7mabove the sector's middle half▲ 23.0%€0.7mabove the sector's middle half▲ 3.2%€0.7mabove the sector's middle half▲ 9.8%€0.8mabove the sector's middle half▲ 9.5%
Solvency19.2%-41.7%▲ 22.4pp49.1%within the sector's middle half▲ 7.5pp55.2%within the sector's middle half▲ 6.1pp61.3%above the sector's middle half▲ 6.1pp66.4%above the sector's middle half▲ 5.0pp
Current ratio3.40-5.27▲ 1.885.62above the sector's middle half▲ 0.359.07above the sector's middle half▲ 3.4411.98above the sector's middle half▲ 2.9213.10above the sector's middle half▲ 1.12
Return on assets (ROA)17.6%-27.4%▲ 9.8pp10.9%within the sector's middle half▼ 16.5pp4.8%within the sector's middle half▼ 6.1pp7.8%within the sector's middle half▲ 3.1pp7.3%within the sector's middle half▼ 0.5pp
above
within
below
the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2023 in colour, 2022 as the grey bar beneath
Assets €1.7m
Fixed assets
€805,153 ▼ 0.9%
Current assets
€878,321 ▲ 8.7%
Equity and liabilities €1.7m
Equity
€1.1m ▲ 12.4%
Debt
€566,283 ▼ 9.6%
Debt's share of the balance-sheet total falls from 38.7% to 33.6%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€177,598▼
2022 · €180,905
Cash flow
€131,564▼
2022 · €133,619
Debt to equity
0.51▼
2022 · 0.63
ROE
11.0%▼
2022 · 12.8%
Interest coverage
18.87▼
2022 · 18.94
Debt ≤ 1 year
€67,059▼
2022 · €67,459
Debt > 1 year
€499,224▼
2022 · €559,131
Income taxes
€36,621▼
2022 · €37,736
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | - | €5,953 | €5,953 | €5,953 | €6,767 | €8,665 | ▲ 28.0% |
| Other operating charges640/8 | - | - | - | €1,416 | €1,233 | €1,824 | ▲ 47.9% |
| Gross operating margin9900 | €31,293 | €224,195 | €250,377 | €113,214 | €182,138 | €179,422 | ▼ 1.5% |
| Operating profit (loss)9901 | €30,946 | €217,341 | €243,604 | €105,845 | €174,138 | €168,933 | ▼ 3.0% |
| Recurring financial income75 | €175,000 | €252,967 | - | - | - | - | - |
| Financial charges65/66B | - | - | - | €10,316 | €9,550 | €9,413 | ▼ 1.4% |
| Recurring financial charges65 | €8,354 | €11,994 | €11,111 | €10,316 | €9,550 | €9,413 | ▼ 1.4% |
| Profit (loss) for the period before taxes9903 | €197,592 | €458,314 | €232,493 | €95,529 | €164,588 | €159,520 | ▼ 3.1% |
| Income taxes67/77 | €4,948 | €53,055 | €56,482 | €20,603 | €37,736 | €36,621 | ▼ 3.0% |
| Profit (loss) for the period9904 | €192,644 | €405,259 | €176,011 | €74,926 | €126,852 | €122,899 | ▼ 3.1% |
| Profit (loss) for the period to be appropriated9905 | €192,644 | €405,259 | €176,011 | €74,926 | €126,852 | €122,899 | ▼ 3.1% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total assets20/58 | €1.1m | €1.5m | €1.6m | €1.6m | €1.6m | €1.7m | ▲ 3.9% |
| Fixed assets21/28 | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | ▼ 0.9% |
| Tangible fixed assets22/27 | - | €0.02m | €0.02m | €0.01m | €0.01m | €0.005m | ▼ 59.3% |
| Furniture and vehicles24 | - | - | - | €0.01m | €0.01m | €0.005m | ▼ 59.3% |
| Financial fixed assets28 | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | €0.8m | = |
| Current assets29/58 | €0.3m | €0.7m | €0.8m | €0.8m | €0.8m | €0.9m | ▲ 8.7% |
| Amounts receivable within one year40/41 | €0.2m | €0.4m | €0.4m | €0.5m | €0.2m | €0.3m | ▲ 50.2% |
| Trade receivables40 | - | - | - | €0.2m | €0.2m | €0.3m | ▲ 50.7% |
| Other amounts receivable41 | - | - | - | €0.3m | €0.02m | €0.03m | ▲ 45.8% |
| Cash at bank and in hand54/58 | €0.03m | €0.2m | €0.3m | €0.2m | €0.6m | €0.5m | ▼ 3.6% |
| Deferred charges and accrued income490/1 | - | - | - | €0.06m | €0.05m | €0.04m | ▼ 18.1% |
| Equity and liabilities | |||||||
| Total equity and liabilities10/49 | €1.1m | €1.5m | €1.6m | €1.6m | €1.6m | €1.7m | ▲ 3.9% |
| Equity10/15 | €0.2m | €0.6m | €0.8m | €0.9m | €1.0m | €1.1m | ▲ 12.4% |
| Contributions10/11 | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | = |
| Reserves13 | €0.002m | €0.002m | €0.002m | €0.002m | €0.002m | €0.002m | = |
| Non-distributable reserves130/1 | - | - | - | €0.002m | €0.002m | €0.002m | = |
| Reserves not available under the articles1311 | - | - | - | €0.002m | €0.002m | €0.002m | = |
| Profit (loss) carried forward14 | €0.2m | €0.6m | €0.8m | €0.8m | €1.0m | €1.1m | ▲ 12.6% |
| Amounts payable17/49 | €0.9m | €0.9m | €0.8m | €0.7m | €0.6m | €0.6m | ▼ 9.6% |
| Amounts payable after more than one year17 | €0.8m | €0.7m | €0.7m | €0.6m | €0.6m | €0.5m | ▼ 10.7% |
| Financial debts170/4 | - | - | - | €0.6m | €0.6m | €0.5m | ▼ 10.7% |
| Amounts payable within one year42/48 | €0.09m | €0.1m | €0.1m | €0.08m | €0.07m | €0.07m | ▼ 0.6% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.06m | €0.06m | €0.06m | ▲ 1.1% |
| Trade debts44 | €0.007m | €0.003m | €0.004m | €0.002m | €0.002m | €0.003m | ▲ 34.1% |
| Suppliers440/4 | - | - | - | €0.002m | €0.002m | €0.003m | ▲ 34.1% |
| Taxes, remuneration and social security45 | - | - | - | €0.02m | €0.001m | €0.001m | ▲ 120% |
| Taxes450/3 | - | - | - | €0.02m | €0.001m | €0.001m | ▲ 120% |
| Other amounts payable47/48 | - | - | - | €0.004m | €0.005m | €0.002m | ▼ 53.2% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Change |
|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €192,644 | €405,259 | €176,011 | €74,926 | €126,852 | €122,899 | ▼ 3.1% |
| + Depreciation and write-downs630 | - | €5,953 | €5,953 | €5,953 | €6,767 | €8,665 | ▲ 28.0% |
| Operating cash flow (approximation) | €192,644 | €411,212 | €181,964 | €80,879 | €133,619 | €131,564 | ▼ 1.5% |
| Investment in fixed assets (approximation) | - | -€29,807 | €0 | €0 | -€7,400 | -€1,232 | ▲ 83.4% |
| Change in cash | - | €123,689 | €126,281 | -€81,374 | €360,416 | -€20,344 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Filings with the National Bank (7)
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2023 | full format | 31-08-2024 | 2024-00458462 |
| 31-12-2022 | full format | 01-09-2023 | 2023-00440235 |
| 31-12-2021 | micro format | 31-08-2022 | 2022-20421814 |
| 31-12-2020 | micro format | 30-08-2021 | 2021-61900049 |
| 31-12-2019 | micro format | 31-12-2020 | 2020-77900595 |
| 31-12-2018 | micro format | 31-12-2020 | 2020-77900594 |
| 31-12-2017 | micro format | 31-08-2018 | 2018-62300185 |
Similar companies · same sector, comparable size
APOTHEEK MARTENS MIREILLE
BE 0870.310.328
Gent · equity €1,117,369
Pharmacie de Warsage
BE 0898.543.266
Dalhem · equity €1,116,561
APOTHEEK DEBRUYNE - DESRUMAUX
BE 0480.099.520
Brugge · equity €1,118,140
Kevin BULKMANS
BE 0835.826.234
Temse · equity €1,119,071
Apotheek Verbist
BE 0429.005.363
Zemst · equity €1,114,108
Of the 5,206 active companies whose main activity is retail sale of pharmaceutical products (NACE 47730), figures are known for 3,875. 2,916 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
No directors read yet: 1 of 2 Gazette acts processed. See the directors and other office holders in the KBO →
Owners and capital
Owners
No owners or capital events in the accounts and acts we read.
History
Acts, filings and financial milestones
2024
31-08
NBB filing
Annual accounts filed
financial year 2023 · full format · 31 days late
28-02
Gazette deed
Amendment of the articles · Legal-form change · Resignations & appointmentsCapital conversion · Legal-form conversion · Kind of shares9 facts ▸
Gazette deed
Amendment of the articles · Legal-form change · Resignations & appointments
Capital conversion · Legal-form conversion · Kind of shares9 facts ▸
- General meeting, 29-12-2023
- Other provision, 08-09-2016
- Other provision, “statuts non modifiés depuis constitution” (deed in French)
- Capital conversion, “capital ancien et réserve légale ancienne disponibles pour distribution, article 39,§2,alinéa 3 loi 23-03-2019 introduisant Code des sociétés et des associati…” (deed in French)
- Amendment of the articles
- Legal-form conversion, “société à responsabilité limitée” (deed in French)
- Kind of shares, “nominative”, 186 (deed in French)
- Director in office, LEDOUX Mathieu (director)
- Power of attorney
2023
31-12
Financial
Equity above €1mequity €1.1m ▲12.4%
A profit in every financial year since 2018 builds equity to €1.1m.
01-09
NBB filing
Annual accounts filed
financial year 2022 · full format · 32 days late
2022
31-08
NBB filing
Annual accounts filed
financial year 2021 · micro format · 31 days late
2021
31-12
Financial
Weakest financial yearnet €74,926 ▼57.4%
Net result drops to €74,926, the lowest in the series; recovery starts the following year.
30-08
NBB filing
Annual accounts filed
financial year 2020 · micro format · 30 days late
2020
31-12
NBB filing
Annual accounts filed
financial year 2019 · micro format · 153 days late
31-12
NBB filing
Annual accounts filed
financial year 2018 · micro format · 519 days late
2019
31-12
Financial
Highest result from 2018 to 2023net €405,259 ▲110%
Net result €405,259, the highest in the series.
31-12
Financial
Equity above €500,000equity €616,503 ▲192%
A profit in every financial year since 2018 builds equity to €616,503.
2018
31-08
NBB filing
Annual accounts filed
financial year 2017 · micro format · 31 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 2 deeds read
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Register details
Identification
Legal formPrivate limited company
Founded08-09-2016
Financial year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Contact
E-mail
math_0612@hotmail.com
Phone
+32486528723
E-invoicing
Reachable via Peppol
Peppol ID
0208:0662445167
Registered
17-12-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 18 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
Location & real-estate footprint
Registered office, Floreffe · 1 establishment unit since 2018
Ground area
2,400 m²
Building footprint
147 m²
Building volume
696 m³
Parcel 92050B0015/00A002, Wallonia · tallest building 5.4 m. Linked by address, not a title deed.
1 establishment unit
Rue de Robersart, Franière 29, 5150 Floreffe
since 2018unit no. 2.284.219.544
1 parcel
Wallonia
1
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 92050B0015/00A002 | Wallonia | 2,400 m² | 1 · 147 m² | 5.4 m · 2 |
How the parcels are linked
Good to know
The parcel matches the address exactly.
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “L’acquisition,la création et l’exploitation d’une ou plusieurs officines; La fabrication et le commerce de tous produits de pharmacie,de…” (deed in French)
7 activities (deed in French)
- L’acquisition,la création et l’exploitation d’une ou plusieurs officines.
- La fabrication et le commerce de tous produits de pharmacie,de biothérapie,de diététique et de soins de santé.
- L’achat et la vente de matières premières.
- L’exécution de toutes prescriptions médicales s’y rapportant.
- Le commerce de tous produits homéopathiques,bandagisterie,ainsi que les accessoires médicaux et d’optique.
- L’acquisition sous toutes ses formes,la gestion et l’aliénation de tous biens mobiliers et immobiliers.
- La constitution et la gestion d’un patrimoine mobilier et immobilier ainsi que toutes activités qui se rapportent directement ou indirectement à ce patrimoine.
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- LT Pharma
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Région wallonne, organe d'administration” (deed in French)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- “F. Pouvoirs et fonctionnement Chaque administrateur a le pouvoir d’accomplir tous les actes nécessaires ou utiles à la réalisation de…”
- Board ruleHow the board is made up, meets and takes decisions.
- “Article 6D, reste en fonction jusqu’à remplacement raisonnable à la demande de la société” (deed in French)“Tous les actes nécessaires ou utiles à la réalisation de l’objet, chaque administrateur” (deed in French)“Pouvoirs spéciaux et limités, un administrateur” (deed in French)5 more provisions on this in the deed
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Autres actionnaires, 40” (deed in French)
- Share issue ruleHow and by whom new shares can be issued.
- “Acte authentique, articles 5:128 et suivants Code des sociétés et des associations” (deed in French)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Friday of June at 19:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Assemblée générale, comme en matière de modification des statuts” (deed in French)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- One provision in the deed